PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immunic Inc | IMUX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.36 | -4.1% | 8.43 | 8.8247 | 8.38 | 8.77 | 8.79 | 18:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 7.03 | 9.19 | 2.16 | 23.5% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 175 | 15,897 | $ 8.53 | $ 135,664 | 30,608 | 8.38 - 22.6626 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:59:43 | 12 | $ 8.39 | USD |
Immunic Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 85.09M | 10.09M | $ -41.48M | -39.20 | - | 9.76M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Immunic News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/15/2019 | 17:03 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/15/2019 | 17:01 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 10/15/2019 | 07:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 10/15/2019 | 06:30 | PR Newswire (US) | Immunic, Inc. Expands Board of Directors with Appointment of.. |
| 10/10/2019 | 16:01 | PR Newswire (US) | Immunic, Inc. Announces Completion of Enrollment for its.. |
| 10/04/2019 | 08:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/30/2019 | 06:30 | PR Newswire (US) | Immunic, Inc. to Participate in Investor and Scientific.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMUX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.12 | 9.47 | 8.38 | 8.99 | 13,722 | -0.69 | -7.57% |
| 1 Month | 12.44 | 13.9077 | 8.38 | 10.29 | 31,233 | -4.01 | -32.23% |
| 3 Months | 13.00 | 17.2424 | 8.38 | 12.66 | 34,816 | -4.57 | -35.15% |
| 6 Months | 17.00 | 19.50 | 8.38 | 13.65 | 100,343 | -8.57 | -50.41% |
| 1 Year | 22.00 | 22.6626 | 8.38 | 13.81 | 105,433 | -13.57 | -61.68% |
| 3 Years | 22.00 | 22.6626 | 8.38 | 13.81 | 105,433 | -13.57 | -61.68% |
| 5 Years | 22.00 | 22.6626 | 8.38 | 13.81 | 105,433 | -13.57 | -61.68% |
Immunic Description
| Immunic Inc is a clinical stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, IMU-935 is an inverse agonist of RORyt and IMU-856 targets the restoration of the intestinal barrier function. |
